Who are Racemic adrenaline's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Ephedrine-S, High-dose epinephrine, Atropine sulfate and epinephrine, Low-dose epinephrine, Epinephrine (Adrenaline), IM epinephrine 1:1000.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/racemic-adrenaline.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Racemic adrenaline — Competitive Intelligence Brief

Racemic adrenaline (Racemic adrenaline) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Sympathomimetic amine; adrenergic agonist. Area: Emergency medicine; Cardiovascular; Respiratory.

marketed Sympathomimetic amine; adrenergic agonist Alpha-1, alpha-2, beta-1, and beta-2 adrenergic receptors Emergency medicine; Cardiovascular; Respiratory Small molecule Live · refreshed every 30 min

Target snapshot

Racemic adrenaline (Racemic adrenaline) — Oslo University Hospital. Racemic adrenaline (epinephrine) activates alpha and beta adrenergic receptors to increase heart rate, blood pressure, and bronchial dilation.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Racemic adrenaline TARGET	Racemic adrenaline	Oslo University Hospital	marketed	Sympathomimetic amine; adrenergic agonist	Alpha-1, alpha-2, beta-1, and beta-2 adrenergic receptors
Ephedrine-S	Ephedrine-S	Dalian Municipal Central Hospital	marketed	Sympathomimetic amine	Alpha-1, alpha-2, beta-1, and beta-2 adrenergic receptors
High-dose epinephrine	High-dose epinephrine	Icahn School of Medicine at Mount Sinai	marketed	Catecholamine; adrenergic agonist	Alpha-1, alpha-2, beta-1, and beta-2 adrenergic receptors
Atropine sulfate and epinephrine	Atropine sulfate and epinephrine	Dar El Oyoun Hospital	marketed	Anticholinergic agent and sympathomimetic amine combination	Muscarinic acetylcholine receptors (atropine); alpha-1, alpha-2, beta-1, and beta-2 adrenergic receptors (epinephrine)
Low-dose epinephrine	Low-dose epinephrine	Icahn School of Medicine at Mount Sinai	marketed	Sympathomimetic amine / Catecholamine	Alpha-1, alpha-2, beta-1, and beta-2 adrenergic receptors
Epinephrine (Adrenaline)	Epinephrine (Adrenaline)	Aga Khan University	marketed	Catecholamine; adrenergic agonist	Alpha-1, alpha-2, beta-1, and beta-2 adrenergic receptors
IM epinephrine 1:1000	IM epinephrine 1:1000	University of Louisville	marketed	Catecholamine; adrenergic agonist	Alpha-1, alpha-2, beta-1, and beta-2 adrenergic receptors

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Sympathomimetic amine; adrenergic agonist class)

Oslo University Hospital · 1 drug in this class
University Hospital, Ghent · 1 drug in this class
University of Parma · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Racemic adrenaline — Competitive Intelligence Brief. https://druglandscape.com/ci/racemic-adrenaline. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab